LACIVITA, ENZA
 Distribuzione geografica
Continente #
NA - Nord America 6.426
AS - Asia 2.340
EU - Europa 1.639
SA - Sud America 672
AF - Africa 54
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.139
Nazione #
US - Stati Uniti d'America 6.333
SG - Singapore 1.014
BR - Brasile 579
CN - Cina 562
HK - Hong Kong 351
SE - Svezia 348
RU - Federazione Russa 230
IT - Italia 227
DE - Germania 222
VN - Vietnam 175
GB - Regno Unito 137
UA - Ucraina 123
FI - Finlandia 114
IN - India 58
ID - Indonesia 49
AT - Austria 47
CA - Canada 42
AR - Argentina 36
MX - Messico 33
FR - Francia 30
NL - Olanda 30
BE - Belgio 26
IE - Irlanda 25
BD - Bangladesh 23
PL - Polonia 21
JP - Giappone 20
EC - Ecuador 19
ES - Italia 19
ZA - Sudafrica 16
VE - Venezuela 15
IQ - Iraq 11
CO - Colombia 10
PK - Pakistan 10
TR - Turchia 10
SA - Arabia Saudita 9
LT - Lituania 8
NO - Norvegia 8
AL - Albania 7
KE - Kenya 7
UZ - Uzbekistan 7
AU - Australia 6
EG - Egitto 6
IR - Iran 6
TN - Tunisia 6
CI - Costa d'Avorio 5
CL - Cile 5
JM - Giamaica 5
KR - Corea 5
PY - Paraguay 5
AZ - Azerbaigian 4
KZ - Kazakistan 4
MA - Marocco 4
CH - Svizzera 3
CR - Costa Rica 3
GE - Georgia 3
JO - Giordania 3
NG - Nigeria 3
PT - Portogallo 3
RO - Romania 3
SY - Repubblica araba siriana 3
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
DM - Dominica 2
ET - Etiopia 2
EU - Europa 2
GY - Guiana 2
HN - Honduras 2
KG - Kirghizistan 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BW - Botswana 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
GI - Gibilterra 1
GR - Grecia 1
GT - Guatemala 1
KW - Kuwait 1
LB - Libano 1
ML - Mali 1
MY - Malesia 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
SN - Senegal 1
TW - Taiwan 1
UY - Uruguay 1
Totale 11.139
Città #
Fairfield 874
Ashburn 577
Woodbridge 565
Singapore 472
Houston 396
Chandler 378
Seattle 375
Hong Kong 345
Cambridge 316
Ann Arbor 312
Wilmington 292
Jacksonville 281
Nyköping 257
Dallas 228
Beijing 183
Roxbury 114
Bari 111
Lawrence 104
Nanjing 97
New York 88
Boardman 80
Princeton 68
Ho Chi Minh City 65
Des Moines 64
Los Angeles 61
Inglewood 55
Brooklyn 49
São Paulo 40
San Diego 39
Jakarta 38
Santa Clara 36
Buffalo 33
Rome 32
Shenyang 28
Vienna 28
London 27
Dublin 26
Dong Ket 25
Hanoi 25
Council Bluffs 24
Brussels 23
Jiaxing 22
Pune 22
Nanchang 21
Frankfurt am Main 20
Hebei 20
Munich 20
Rio de Janeiro 20
Warsaw 20
Chicago 19
Nuremberg 19
Changsha 17
Paris 17
Unterföhring 17
Helsinki 16
Norwalk 14
Tianjin 14
Shanghai 13
Turku 13
Columbus 12
Curitiba 12
Montreal 12
The Dalles 12
Tokyo 12
Dearborn 11
Falls Church 11
Phoenix 11
Toronto 11
Belo Horizonte 10
Brasília 10
North Bergen 10
San Francisco 10
Boston 9
Fortaleza 8
Indiana 8
Johannesburg 8
Moscow 8
Naples 8
Salt Lake City 8
Santiago de Compostela 8
Stockholm 8
Bjørkelangen 7
Denver 7
Goiânia 7
Groningen 7
Guarulhos 7
Guayaquil 7
Haiphong 7
Hải Dương 7
Langenzersdorf 7
Mexico City 7
Redwood City 7
Tashkent 7
Campinas 6
Manchester 6
Nairobi 6
Orem 6
Quito 6
Sorocaba 6
Abidjan 5
Totale 7.897
Nome #
Structure-Activity Relationships and Therapeutic Potentials of 5-HT7 Receptor Ligands: An Update 193
Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2 180
Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics. 179
Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X Syndrome 170
5-HT7 receptor activation: procognitive and antiamnesic effects 167
Analogues of σ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Added Polar Functionality and Reduced Lipophilicity for Potential Use as Positron Emission Tomography Radiotracers 162
Activation of 5-HT7 receptor by administration of its selective agonist, LP-211, modifies explorative-curiosity behavior in rats in two paradigms which differ in visuospatial parameters 162
Long-lasting beneficial effects of central serotonin receptor 7 stimulation in female mice modeling Rett syndrome. 161
Persistent modification of forebrain networks and metabolism in rats following adolescent exposure to a 5-HT7 receptor agonist 157
5 HT1A receptor, an old target for new therapeutic agents 152
11C-Labeling of N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide derivatives and evaluation as potential radioligands for PET imaging of dopamine D3 receptors 147
ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. 146
3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: Molecular modeling of chiral recognition by FPR2. 145
Activation of Serotonin 5-HT7 Receptors Modulates Hippocampal Synaptic Plasticity by Stimulation of Adenylate Cyclases and Rescues Learning and Behavior in a Mouse Model of Fragile X Syndrome 143
POLYCYCLIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF 136
5-HT7 receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009) 134
Activatable fluorescent probes: a new concept in optical molecular imaging 131
Novel Derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Improved Fluorescent and σ Receptors Binding Properties 131
Bivalent ligand approach on 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine: Synthesis and binding affinities for 5-HT7 and 5-HT1A receptors 130
Stimulation of the brain serotonin receptor 7 rescues mitochondrial dysfunction in female mice from two models of Rett syndrome 129
Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress 129
Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2. 127
Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder 127
Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide. 125
The 5-HT7 receptor triggers cerebellar long-term synaptic depression via PKC-MAPK 121
Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions 120
Aurantiamide-related dipeptide derivatives are formyl peptide receptor 1 antagonists 120
The brain-penetrant 5-HT7receptor agonist LP-211 reduces the sensory and affective components of neuropathic pain 114
LP-211, a selective 5-HT7receptor agonist, increases novelty-preference and promotes risk-prone behavior in rats 114
Structural Determinants in the Binding of BB2 Receptor Ligands: In Silico, X-Ray and NMR Studies in PD176252 Analogues. 114
Interplay between Serotonin 5-HT1A and 5-HT7 Receptors in Depressive Disorders. 112
4-[omega-[4-arylpiperazin-1-yl]phenyl)imidazo[1,2-a]pyridine derivatives: fluorescent high-affinity dopamine D3 receptor ligands as potential probes for receptor visualization 111
Structural modifications of the serotonin 5-HT7 receptor agonist N -(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve in vitro microsomal stability: A case study 110
G-protein coupled receptors involved in the resolution of inflammation: Ligands and therapeutic perspectives 110
Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters 108
LP-211 is a brain penetrant selective agonist for the serotonin 5-HT7 receptor 107
Structural insights into serotonin receptor ligands polypharmacology 107
Synthesis, radiolabeling and in vivo evaluation of [11C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT7 receptor 105
The therapeutic potential of 5-HT1A receptors: a patent review. 104
Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT₇ receptor. 104
The microRNA-29a Modulates Serotonin 5-HT7 Receptor Expression and Its Effects on Hippocampal Neuronal Morphology 104
Investigations on the 1-(2-biphenyl)piperazine motif. Identification of new potent and selective ligands for the serotonin7 (5-HT7) receptor with agonist or antagonist action in vitro or ex vivo. 103
The arylpiperazine derivatives N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT7 receptor binding and cAMP signaling. 102
N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands 101
Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders 101
Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview. 101
BEHAVIOURAL EFFECTS OF TWO NOVEL AGONISTS FOR SEROTONIN RECEPTOR 7 IN MICE 99
Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome 99
Serotonin 5-HT7 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons 97
Novel 64Cu Labeled RGD2-BBN Heterotrimers for PET Imaging of Prostate Cancer 97
Differential responses to acute administration of a new 5-HT7-R agonist as a function of adolescent pre-treatment: phMRI and immuno-histochemical study. 95
Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice 95
Emotional and risk seeking behavior after prepuberal subchronic or adult acute stimulation of 5-HT7-Rs in naples high excitability rats. 95
Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation 95
Selective 5-HT7 receptor agonists LP 44 and LP 211 elicit an analgesic effect on formalin-induced orofacial pain in mice 94
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function 92
The medicinal chemistry of 5-HT2C receptor ligands 91
Stimulation of 5-HT7 receptor during adolescence determines its persistent upregulation in adult rat forebrain areas 91
Determination of 1-aryl-4propylpiperazine pKa values: the substituent on aryl modulates basicity 90
Increase of Capsaicin-Induced Trigeminal Fos-Like Immunoreactivity by 5-HT(7) Receptors. 90
Synthesis and Biological Evaluation of Potential Positron Emission Tomography (PET) Ligands for Brain Visualization of Dopamine D3 Receptors. 89
Prior Activation of 5-HT7 Receptors Modulates the Conditioned Place Preference With Methylphenidate 87
Potentiation of capsaicin-induced neurogenic inflammation by 5-HT7 receptors in the rat hind paw: Involvement of calcitonin gen-related peptide 87
Allosteric Modulators of Serotonin Receptors: A Medicinal Chemistry Survey 86
Developments in fluorescent probes for receptor research 85
Prepuberal Stimulation of 5-HT7-R by LP-211 in a Rat Model of Hyper-Activity and Attention-Deficit: Permanent Effects on Attention, Brain Amino Acids and Synaptic Markers in the Fronto-Striatal Interface. 84
Mitochondrial membranes of human SH-SY5Y neuroblastoma cells express serotonin 5-HT7 receptor 82
Synthesis and biological evaluation of potential positron emission tomography (PET) ligands for brain visualization of dopamine D3 receptors 81
Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II 81
Identification of a red-emitting fluorescent ligand suitable for in vitro 5-HT1A receptor visualization 80
FPR2 and brimstone: a novel approach for the treatment of neuroinflammation 79
Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors 79
N-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 ligands 78
New 1-arylpiperazinic ligands of 5-HT7 receptor and use thereof 76
Radiosynthesis and in vivo Evaluation of Carbon-11 (2S)-3-(1H-Indol-3-yl)-2-[(4-methoxyphenyl)carbamoyl]amino-N-[1-(5-methoxypyridin-2-yl)cyclohexyl]methylpropanamide: An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neuroinflammation 76
trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT1A receptor ligands as conformationally constrained analogs of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines 74
Privileged scaffold-based design to identify a novel drug-like 5-HT7 receptor-preferring agonist to target Fragile X syndrome 73
Selective Agents for Serotonin2C (5-HT2C) Receptor 72
The contribution of formyl peptide receptor dysfunction to the course of neuroinflammation: A potential role in the brain pathology 71
N-[omega-[4-(2-Methoxyphenyl)-1-piperazinyl]alkyl]-2-quinolinamines as High-Affinity Fluorescent 5-HT1A Receptor Ligands 70
Design and synthesis of arylpiperazine-based fluorescent ligands for serotonin 5-HT1A and dopamine D3 receptors. 69
null 68
Pharmacological Stimulation of the Brain Serotonin Receptor 7 as a Novel Therapeutic Approach for Rett Syndrome. 68
First structure–activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure 67
Development of a PET radioligand for the 5-HT7 receptor. Preliminary characterization using autoradiography 66
Modulatory effects following subchronic stimulation of brain 5-HT7-R system in mice and rats. 66
Behavioral, Anti-Inflammatory, and Neuroprotective Effects of a Novel FPR2 Agonist in Two Mouse Models of Autism 65
PREVENTION AND TREATMENT OF RETT SYNDROME 65
N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides as 5-HT7 receptor agents 64
Design, synthesis, radiolabeling and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential Positron Emission Tomography tracer for the dopamine D4 receptors 63
The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Improves Ex Vivo and In Vivo Amyloid Beta (1–42)-Induced Neuroinflammation in Mouse Models of Alzheimer’s Disease 61
Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders 61
Inflammaging and Immunosenescence in the Post‐COVID Era: Small Molecules, Big Challenges 60
Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists 60
N-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 ligands 60
Design, synthesis, radiolabeling and in vivo biological evaluation of potential 5-Ht7 receptor PET tracers: Structural modifications of the selective agonist Lp-211 60
The GR-127935-sensitive mechanism mediating hypotension in anesthetized rats: are 5-HT5B receptors involved? 60
5-HT7 Receptors Regulate Excitatory-Inhibitory Balance in Mouse Spinal Cord Dorsal Horn 59
Design synthesis, and binding affinity of potential positron emission tomography (PET) ligands for visualitation of brain dopamine D3 receptors 59
Selective serotonergic 5-HT7 receptor agonists as a new therapeutic venue for treatment of cognitive disorders: focus on Fragile X syndrome. 59
Totale 10.126
Categoria #
all - tutte 49.725
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.725


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021684 0 0 0 0 0 53 135 91 79 161 81 84
2021/2022900 51 115 29 34 41 67 46 49 84 47 150 187
2022/20231.134 203 94 77 89 154 146 16 130 172 4 25 24
2023/2024415 28 76 26 12 31 99 13 14 26 17 19 54
2024/20252.089 62 11 188 74 59 147 201 177 110 100 330 630
2025/20262.461 660 309 466 535 393 98 0 0 0 0 0 0
Totale 11.496